Horizon Discovery and Domainex Ltd Collaborate to Support Lead Optimization Oncology Program

Horizon’s isogenic cell lines accurately modeling tumor mutations to be used to profile lead compounds

08-Aug-2012 - United Kingdom

Horizon Discovery Ltd  announced it has signed an agreement with Domainex to support Domainex’s TBK1/ IKKe oncology research and development program, which is conducted in collaboration with The Institute of Cancer Research, London. Under the terms of the agreement, Horizon will profile a number of lead compounds against a panel of X-MAN™ isogenic disease model human cell lines, which accurately model the mutations found in cancer cells.

Profiling of Domainex’s lead TBK1/IKKe dual inhibitor molecules against the X-MAN cell lines will enable identification of the effect of individual mutations on drug activity and resistance and prediction of which patient sub-groups will respond.  This will help guide the medicinal chemistry optimization program and will provide important patient stratification data for future partnering.

Financial terms of the agreement are not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances